Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm(Düsseldorf University Hospital), Jonathan W. Uhr(The University of Texas Southwestern Medical Center)
Cited by 195
Related Papers
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients
|BMC Cancer|2019|20
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
|The Oncologist|2022|13